Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“I’m thrilled to share that Pfizer has entered into a definitive agreement to acquire Metsera, a clinical-stage biopharmaceutical company accelerating an exciting next generation of investigational medicines for obesity and cardiometabolic diseases.
Metsera’s innovative injectable and oral peptide portfolio brings differentiated science and a scalable platform that has the potential to transform the obesity treatment landscape, potentially delivering best-in-class efficacy and safety profiles in a monthly dosing format.
Obesity and the over 200 diseases associated with excess weight continue to represent an important area of unmet need. With Pfizer’s proven track record of establishing leadership, we plan to apply our expertise in drug development, manufacturing and commercialization to advance Metsera’s pipeline to deliver their differentiated long-acting peptide candidates.
The transaction with Metsera is expected to close in the fourth quarter of 2025, subject to the fulfillment of customary closing conditions. We look forward to sharing more about our efforts as things progress.
Learn more about this announcement.”
More posts featuring Chris Boshoff.